A multi-institutional research team led by Central South University (CSU) and The Chinese University of Hong Kong (CUHK) has unveiled the most comprehensive genomic analysis to date of… read more.
New research by UCLA Health found GLP-1 medications may reduce the risk of serious fractures for adults with type 2 diabetes. Adults with type 2 diabetes and obesity… read more.
Moderna, Inc. announced that the FDA has approved Mflusiva (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows… read more.
GE HealthCare announced the launch of Invenia Abus (Automated Breast Ultrasound) Prime and Abus StreamVue, a redesigned enterprise viewer that recently received FDA 510(k) clearance and CE Marking,… read more.
Arcutis Biotherapeutics announced that the FDA has approved the supplemental New Drug Application (sNDA) to expand the indication for Zoryve (roflumilast) cream 0.3% for the topical treatment of… read more.
Genmab A/S announced that the European Commission (EC) granted marketing authorization for Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (Tepkinly + R2) for the treatment of adult… read more.
New peer-reviewed publications find significant gaps in lip product regulation and safety testing, including reliance on inappropriate skin models and significant underestimation of usage and ingestion rates, leaving… read more.
Letters to patients from ophthalmology services—-the highest volume outpatient specialty in UK healthcare—include too much complex language and medical terminology which patients are likely to find hard to… read more.
Novartis announced the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for patients with prostate-specific membrane antigen (PSMA)-positive metastatic… read more.
AbbVie announced that the EC has approved Rinvoq (upadacitinib; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients 12 years and older… read more.
Arcutis Biotherapeutics announced that the FDA has accepted its supplemental New Drug Application (sNDA) for Zoryve (roflumilast) cream 0.05% to expand the indication for the topical treatment of… read more.
Novartis announced that the European Commission (EC) has approved Itvisma (onasemnogene abeparvovec) for the treatment of children two years and older, teens and adults living with spinal muscular… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
